Sanofi stock
Price history
−2.17% over the period1 year: from €89.89 (November 17, 2025) to €87.94 (November 17, 2026), −2.17%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | €87.94 |
| October 30, 2026 | €79.74 |
| September 30, 2026 | €72.64 |
| August 31, 2026 | €76.81 |
| July 31, 2026 | €74.47 |
| June 30, 2026 | €75.08 |
| May 29, 2026 | €75.29 |
| April 30, 2026 | €79.82 |
| March 31, 2026 | €82.72 |
| February 27, 2026 | €82.20 |
| January 30, 2026 | €79.20 |
| December 31, 2025 | €82.72 |
| November 28, 2025 | €85.76 |
| November 17, 2025 | €89.89 |
At a glance
The company
Develops, manufactures and markets therapeutic solutions and vaccines for immunology, rare diseases, neurology and oncology
Latest results
Quarter to September 30, 2026 · EPS €3.55 (estimate €2.79)
Next event
TickerLandia's take on Sanofi
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 14 vs a median of 19 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 26 vs 22 (+19%) in a group of 10.
- Strong point: Dividend (75/100 in its group). Weak point: Profitability (30/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.90% from the 52-week high
Analysts · 24 analysts
Average target€96.36+11.32% vs. price
Buy 12 · Hold 12 · Sell 0 · Buy
TickerLandia Fingerprint: Sanofi
Compared with similar companies: low price, high dividend, and low profitability.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow21
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 25.5 54 EV/EBITDA 8.14 18 Price/book 1.45 6 Forward P/E 9.34 6 Price/sales 2.08 18 Profitabilitylow30
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 22.3% 22 Net margin 8.2% 26 ROE 5.7% 23 Gross margin 74.3% 62 ROA 5.5% 18 Earnings stabilityaverage54
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 4.5% 54 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthaverage57
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +15.70% 74 Earnings growth (year over year) +9.40% 52 Average revenue growth (3 years) +5.04% 46 Financial strengthaverage55
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 0.99 58 Interest coverage 18.2 58 Debt/equitycounts in reverse: lower means more financial strength 0.27 77 Current ratio 1.12 26 Dividendhigh75
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 4.7% 94 Payout ratiopays out more than its earnings 119.1% 81 Consecutive dividend years 27 years 50 Market momentumstrong69
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +16.87% 90 Relative strength (6 months) +12.29% 80 1-year return −3.70% 27 Distance from 200-day average +12.47% 78 Risklow31
How much the price swings.
Metric Value Position in group Volatility (60 days) 23.1% 32 Beta (1 year) 0.40 19 Maximum drawdown (12 months) 22.1% 42
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sanofi is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Sanofi's P/E today is 13.8, below the median of its last 10 fiscal years (19.3; between 8.01 and 40.0 from 2016 to 2025). Sanofi's P/E (trailing 12 months): 25.5, +19% against the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | Sanofi | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 25.5 | Middle | |
| Forward P/E | 9.34 | Low | |
| Operating margin | 22.3% | Middle | |
| ROE | 5.7% | Low | |
| Debt/equity | 0.27 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Sanofi. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€15.23B
Latest quarter · Q3 2026
Net income
€3.02B
Latest quarter · Q3 2026
Quarterly net margin
19.8%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €106.04B
- P/E
- 25.5
- EPS
- €3.46
- Volume
- 1.52M
- Daily trading
- €228.21M
- Dividend yield
- 4.76%
- Last ex-dividend on May 5, 2026
How Sanofi is changing
All resultsRevenue grew 4.6% a year on average over the last 5 years
Operating margin fell from 25.2% to 13.6%
Profits turn into cash: free cash flow equal to 133% of net income
Returns
Sanofi returns with dividends
€1,000 invested in Sanofi 5 years ago, on November 17, 2021, would be worth €1,200 today with dividends reinvested: +20.01% in total, +3.72% per year. On price alone it would be €976 (−2.41%).
| Period | Sanofi | CAC 40 | €1,000 becomes |
|---|---|---|---|
| 1 month | +23.84% | +5.35% | €1,238 |
| 6 months | +17.04% | +4.23% | €1,170 |
| Year to date | +6.31% | +1.71% | €1,063 |
| 1 year | +3.27% | +2.09% | €1,033 |
| 3 years | +17.29% | +14.59% | €1,173 |
| 5 years | +20.01% | +15.82% | €1,200 |
| 10 years | +70.70% | +83.07% | €1,707 |
Over the last 6 months it has done better than 45% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. CAC 40: price only. Calculate your investment
The chart in detail
Sanofi: technical analysis
Sanofi shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 21.0% below its all-time closing high (€109.62, March 7, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 71
- Above 70: a strong rise in a short time
- vs 200-session average
- +12.47%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since October 30, 2026
Support and resistance
Price areas where Sanofi has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€86.56
- Support€83.90−3.07%2 touches, last on April 23, 2026
- Support€82.57−4.60%2 touches, last on February 27, 2026
- Support€79.77−7.84%2 touches, last on August 26, 2026
Volatility and risk
Over the last year it has moved less than the CAC 40.
- Beta (1 year) vs CAC 40
- 0.40
- Volatility (60 sessions, annualised)
- 23.1%
- Largest fall in the last year
- −22.14%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Sanofi: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Sanofi has been July: +2.16% on average, positive in 21 years out of 37. The weakest has been August: −0.98% on average, positive in 21 years out of 37. November, the current month, has been positive in 19 years out of 36 (+0.87% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.09% | −0.75% | 16 of 36 |
| February | −0.58% | −0.85% | 17 of 37 |
| March | +1.77% | +1.31% | 22 of 37 |
| April | +1.69% | +0.82% | 21 of 37 |
| May | −0.85% | −1.24% | 14 of 37 |
| June | −0.91% | −1.02% | 17 of 37 |
| July | +2.16% | +0.82% | 21 of 37 |
| August | −0.98% | +0.95% | 21 of 37 |
| September | +1.12% | +0.54% | 20 of 37 |
| October | +1.94% | +2.67% | 25 of 37 |
| November | +0.87% | +0.64% | 19 of 36 |
| December | +2.12% | +3.84% | 24 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Sanofi and its competitors
Employing 74,846 people, Sanofi researches, develops, manufactures and markets therapeutic solutions, with a focus on immunology and inflammation, rare diseases, neurology, oncology and vaccines. Its vaccine range includes pediatric vaccines against polio, pertussis and Hib, a hexavalent combination vaccine, protection against respiratory syncytial virus and the Fluzone flu vaccine. Dupixent, developed with Regeneron for diseases driven by type 2 inflammation, is one of its products.
- Headquarters
- Paris, France
- Employees
- 74,846
- Founded
- 1994
- Chief executive
- Belen Garijo Lopez
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| SanofiSAN | $116.52B | 22.3% | 25.5 | +17.04% |
| GSKGSK | $102.04B | 30.5% | 18.0 | +0.35% |
| Novo NordiskNOVO.B | $184.87B | 50.8% | 11.2 | −7.92% |
| BayerBAYN | $61.54B | 16.5% | — | +48.87% |
| AstraZenecaAZN | $287.12B | 25.8% | 26.6 | +1.25% |
| NovartisNOVN | $305.16B | 34.0% | 32.6 | +14.23% |
Same industry or related industries, similar size. Compare Sanofi with its competitors · Full profile
